亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文


Icotinib hydrochloride is a National Class 1.1 new drug that is independently developed by Betta Pharmaceuticals Co., Ltd. for nearly a decade. It is also China's first small molecule targeted anti-cancer drug. Icotinib is a potent and highly selective oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and it is used for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients carrying EGFR mutations. 
On June 7th, 2011, Icotinib hydrochloride was approved by the National Medical Products Association (NMPA), fulfilling the unmet medical needs in China.
On August 12th, 2011, the market launch of Icotinib hydrochloride was held in the Great Hall of the People in Beijing. It was praised as a groundbreaking scientific and technological achievement in the China healthcare industry.
In 2012, Icotinib hydrochloride was included on Citeline’s “Pharm R&D Annual Review for 2012”, which was the first time a Chinese innovative drug was included on such report.
On August 13th, 2013, the phase III ICOGEN clinical trial results of Icotinib hydrochloride were published on the Lancet Oncology (Shi, Y., et al., The Lancet Oncology 14 (10) p953-961). Professor of the University of Colorado, Dr. David Camidge, commented that Icotinib has opened a new era of anticancer drug research in China, which is a significant milestone in the global oncology research.

1698306007803090.png

In 2012 and 2014, icotinib hydrochloride won the Golden Prize of Chinese Patent Award for its composition of matter and the crystal form patents.
In 2015, icotinib hydrochloride won “First Prize of National Science and Technology Progress Award 2015”.
In 2016, icotinib hydrochloride won “Chinese Industry Award”. In the same year, it was included in the first round of the price negotiation with the Chinese National Health Commission and created a new model for medical insurance negotiation, which reduced the burden of Chinese patients.
In 2017, icotinib hydrochloride was enlisted on the National Reimbursement Drug List (NRDL). On July 19th, the BRAIN clinical study results of icotinib hydrochloride for NSCLC brain metastasis treatment were published in the Lancet Oncology (Jin-Ji, Y., et al., The Lancet Oncology 5 (9) p707-716). It is the first phase III study of EGFR TKI targeting NSCLC patients with brain metastasis, and this treatment is recommended in the clinical guide. On August 23rd, the first-line clinical study of icotinib hydrochloride in NSCLC patients carrying EGFR mutations was published in the Annual of Oncology, which provided clinical support for its use in the first-line setting.
In 2018, icotinib hydrochloride was included on the National Essential Drug List (EDL), giving access to more Chinese patients.
In 2019, icotinib hydrochloride was included on the General Drug Access Catalogue of National Medical Insurance, further reducing the economic burden of NSCLC patients.



1.png

主站蜘蛛池模板: 97精品人妻酒店综合大胆无码 | 久久精品无码亚洲一区二区 | 午夜福利日本一区二区无码 | AV一区二区三区无码 | 人妻av综合天堂一区 | 国产精品成人无码一区二区 | 亚洲精品无码色情AV在线观看 | 久久精品熟女亚州AV麻豆 | 精品国产精品国产自在久国产 | 亚洲国产精品一区二区三区在线观看 | 成人网站在线观看 | 日本真人边吃奶边做爽免费视频 | 中文字幕无码热在线视频 | 精品国产乱码久久久久久蜜桃免费 | 高清无码在线视频 | 亚欧精品一区二区三区四区 | 国产亚洲精品美女 | 巨爆乳中文字幕爆乳区 | 狠狠躁天天躁夜夜躁婷婷 | 国产又色又爽又免费的刺激软件 | 久久精彩视频网站 | 囯产极品美女高潮无套久久久 | 香港三级韩国三级日本三级 | 91精品国产一区二区三区免费 | 精品人无码一区二区三区 | 18禁成人黄网站免费观看自慰 | 911精品国产自产在线观看 | 人妻体验按摩到忍不住哀求继续 | 国产成人无码区在线观看 | 久久精品国产亚洲v高清色欲 | 厨房少妇人妻好深太紧了 | 国产精品亚洲一区二区三区在线我传媒不卡 | 亚洲欧美一区二区不卡国产 | 久久精品熟女亚州AV麻豆 | 麻豆网站 | 精品人妻久久一区二区三区 | 精品人妻午夜一区二区三区四 | 欧美一区二区三区婷婷月色 | 欧美亚洲日韩高清无码 | 女人国产香蕉久久精品 | 国产v欧美日韩v |